An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease

Official title

A Phase 1b/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy Following Fosigotifator Administration in Adult and Pediatric Subjects With Vanishing White Matter Disease

Overview

Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This is a 201-week, open-label, multiple cohort study enrolling adults, pediatric and infant participants with Vanishing White Matter disease. Participants will attend regular visits during the course of the study and complete medical assessments, blood tests, questionnaires, and be evaluated for side effects.

Interventions

• Drug Fosigotifator
  Oral Use

Primary outcome measures

• Incidence of Treatment-Emergent Adverse Events [Time frame: Baseline up to Approximately Day 28]
• Number of Participants with Change in Vital Signs [Time frame: Baseline up to Approximately Day 28]
• Number of Participants with Change in ECG [Time frame: Baseline up to Approximately Day 28]
• Number of Participants with Change in Clinical Laboratory Tests [Time frame: Baseline up to Approximately Day 28]
• Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) [Time frame: Baseline up to Approximately Day 28]
• Plasma Concentration of Fosigotifator [Time frame: Baseline up to approximately Week 96]
• Time to Cmax (Tmax) of Fosigotifator [Time frame: Baseline up to approximately Week 96]
• Area Under the Plasma Concentration-Time Curve (AUC0-24h) of Fosigotifator [Time frame: Baseline up to approximately Week 96]
• Trough Concentration (Ctrough) of Fosigotifator [Time frame: Baseline up to approximately Week 96]
• Terminal Elimination Half-Life (t1/2) of Fosigotifator [Time frame: Baseline up to approximately Week 96]

Secondary outcome measures (6)

• Incidence of Treatment-Emergent Adverse Events [Time frame: Baseline up to Approximately Week 197]
• Number of Participants with Change in Vital Signs [Time frame: Baseline up to approximately Week 197]
• Number of Participants with Change in ECG [Time frame: Baseline up to approximately Week 197]
• Number of Participants with Change in Clinical Laboratory Tests [Time frame: Baseline up to approximately Week 197]
• Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) [Time frame: Baseline up to approximately Week 197]
• Number of Participants with Change in Magnetic Resonance Imaging (MRI) [Time frame: Baseline up to approximately Week 192]

Eligibility criteria

Inclusion criteria

• Males and females >= 6 months of age at the time of Screening.
• Have VWM disease defined as:

• A clinical diagnosis by a physician experienced in the assessment of VWM disease; and
• A molecular diagnosis of VWM disease, and
• A magnetic resonance imaging (MRI) presentation consistent with VWM disease.
• Have a designated caregiver who is able to complete the respective caregiver-centered assessments.
• Signed and dated informed consent provided by the participant, or from a legally authorized representative (LAR) if participant is incapable to consent themselves.
• Participants must meet criteria (a) and at least one of the following functional criteria (b or c):

• Medical history of at least 1 neurological symptom that is assessed by the investigator as having a reasonable possibility of being related to VWM disease.
• Motor criteria defined as inability to walk 10 or more steps with or without light support of 2 hands
• Cognitive criteria as assessed by the age-appropriate version of the Wechsler Intelligence Scale, with participants scoring < 50 on specific indices; specific details can be provided by the Study physician.
• Pediatric participants in Cohort 4 must meet both criteria a and b below, or criterion c:

• Medical history of at least 1 neurological symptom that is assessed by the investigator as having a reasonable possibility of being related to VWM disease.
• Motor criteria as defined below:

i. More than minimal head control as demonstrated by: While in prone position, the participant can lift his/her head and sustain the position for 10 seconds and bring his/her arms actively to weight bearing in that position.

c. Presymptomatic and homozygous for Cree Leukoencephalopathy (EIF2B5 R195H) or other mutation with known imminent risk of significant clinical decline or death (sponsor must be notified and provide approval prior to screening and enrolling a participant that meets eligibility with only this criterion).

• All male participants who are sexually active and not surgically sterilized must agree to use an acceptable contraceptive method. Additionally, male participants must agree to not donate sperm during the study until 30 days after the final dose of study drug.
• All female participants who are sexually active and of childbearing potential must agree to use a highly effective contraceptive method. Additionally, female participants must agree to not donate eggs during the study and for 30 days after the final dose of study drug.

Exclusion criteria

• Pediatric participants >= 6 months and < 6 years of age must not be on any form of respiratory support at the time of Screening.
• Changes in medication use for the management of VWM disease symptoms within the 4 weeks preceding Screening.
• Seizure disorder not considered adequately controlled by the investigator within the 6 months preceding Screening.
• Participant who, in the opinion of the investigator, is incapable of completing study-required visits and procedures to assess primary and secondary endpoints.
• Adult female participants who are pregnant, breastfeeding or providing breast milk.
• Treatment with any other investigational treatment within 30 days or 5 half-lives (whichever is longer) prior to Baseline.
• Any clinically significant laboratory or imaging findings at Screening.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 3 centers

• Massachusetts General Hospital /ID# 270960 — Boston
• Children's Hospital of Philadelphia — Philadelphia
• University of Utah /ID# 255624 — Salt Lake City

Canada · 1 center

• McGill University Health Centre - Glen Site — Montreal

Netherlands · 1 center

• Amsterdam UMC, locatie VUmc /ID# 270955 — Amsterdam

Identifiers

NCT: NCT05757141 · M23-523 · 2023-505704-30-00

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗